This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
by Zacks Equity Research
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More
by Kinjel Shah
Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
by Zacks Equity Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Sundeep Ganoria
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
by Zacks Equity Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
by Zacks Equity Research
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
by Zacks Equity Research
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
by Zacks Equity Research
With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
Why Is Bausch (BHC) Down 11.2% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
by Zacks Equity Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
by Zacks Equity Research
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA
by Zacks Equity Research
Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.
AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.
TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.
J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug
by Zacks Equity Research
J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up
by Zacks Equity Research
TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.
Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.